@FierceBiotech: Join @FiercePharma's @EricPFierce & @EPVantage's @JonEPVantage today, 2pm ET for an #ASCO14 chat. Follow #FierceASCO. | Follow @FierceBiotech
@JohnCFierce: ICYMI yesterday: Trevi, Complexa bag $38M in VC cash to hit the gas on R&D. Story | Follow @JohnCFierce
@DamianFierce: Forgot @BayerHealthCare's pharma boss is leaving for International Flavors & Fragrances, which sounds like smthng RZA would boast of having. | Follow @DamianFierce
@EmilyMFierce: ICYMI: Nektar reports tumor reduction in preclinical study. Story from FierceBiotech Research | Follow @EmilyMFierce
> Bayer has recruited Otsuka Pharmaceuticals' Dieter Weinand to lead its pharmaceuticals division once Andreas Fibig steps down in August. Story
> Vertex Pharmaceuticals' ($VRTX) cystic fibrosis treatment ivacaftor performed well in a proof-of-concept study on patients with a non-R117H residual function mutation, and now the company is plotting a Phase III monotherapy trial. More
> French biotech Flamel ($FLML) said it has addressed the issues that led to an FDA rejection of its Éclat- acquired treatment and expects to resubmit soon. News
Medical Device News
@FierceMedDev: Medtronic considers bid for Smith & Nephew amid building med dev merger mania. Report | Follow @FierceMedDev
@VarunSaxena2: ICYMI yesterday: Surgical instruments that improve cellulite will get FDA downgrade. Article | Follow @VarunSaxena2
@MichaelGFierce: Singapore team designs nanotechnology glaucoma treatment for sustained release. More from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: Mind-controlled exoskeleton with a 3D-printed helmet could make its debut at the World Cup opening ceremony. Story from The Atlantic | Follow @EmilyWFierce
> Delaying valve replacement procedures could adversely impact high-risk patients. Article
> Study supports clinical guidelines on ICD usage. Story
Pharma News
@FiercePharma: ICYMI: This week's issue of FiercePharmaMarketing. Report | Follow @FiercePharma
@TracyStaton: Would you pay $84K for Sovaldi yourself if you had hep C? Check out this discussion FiercePharma's LinkedIn group. More | Follow @TracyStaton
@EricPFierce: Interesting dissection of Valeant's 'opaque' biz model from ProPublica's Jesse Eisinger. Story | Follow @EricPFierce
@CarlyHFierce: Russia mulls taking $300M in state vaccine contracts local. FierceVaccines story | Follow @CarlyHFierce
@JustinHFierce: Zoetis Animal Health $ZTS traded up 0.35% during mid-day and hit $31.36, upgraded by Zacks from an underperform. More | Follow @JustinHFierce
> Glaxo settles multi-state off-label marketing probe with $105M fine. Article
> Bayer drafts Otsuka exec to lead pharma biz to big growth. Story
Vaccines News
> GAVI nets $50M for Merck's Gardasil, GSK's Cervarix. News
> Scripps, U. of Nebraska-Lincoln win $15M to advance HIV vaccines. Article
> PharmAthene anthrax vax aces survival in rabbit study. Item
> Study: Cholera vaccine has 86% effectiveness rate. Story
> Amgen to pursue T-Vec approval despite PhIII survival miss. More
Pharma Manufacturing News
> Vietnam bans products from 45 Indian companies for failing to meet standards. Item
> Turkey's drugmakers expand manufacturing as market booms. More
> Amneal said to be negotiating to buy Indian sterile injectable manufacturer. Report
> Glenmark opens new mAb manufacturing facility in Switzerland. Article
> AbbVie API expansion in Ireland readies it for anticipated hep C treatment. Story